Latest news with #MounjaroKwikpen
Yahoo
3 days ago
- Business
- Yahoo
Eli Lilly Fires Up GLP-1 Race in India With Mounjaro Pen Launch
Eli Lilly (NYSE:LLY) has rolled out its best-selling diabetes drug Mounjaro in a new injector pen format in India, intensifying its battle with Novo Nordisk in the fast-growing GLP-1 market. The Mounjaro Kwikpen, approved in June for six dose strengths from 2.5 mg to 15 mg, starts at ?14,000 ($160) for the lowest dose and rises to ?27,500 for the highest. Novo Nordisk's (NYSE:NVO) Wegovy, launched just days earlier in a similar format, is priced nearly in line across comparable doses. Warning! GuruFocus has detected 4 Warning Signs with VG. Lilly first entered India's obesity and diabetes market in March with Mounjaro vials and has already seen rapid uptake sales jumped 60% in May from April, according to Pharmarack Technologies. With both companies now offering user-friendly injector pens, competition is set to heat up in a country with more than 100 million diabetics and a rising obesity burden. Analysts see India as a key growth market for GLP-1 drugs as lifestyle diseases climb and awareness of newer therapies expands. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Recorder
3 days ago
- Health
- Business Recorder
Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk. Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device. Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply. The smallest two doses are priced at 14,000 and 17,500 rupees, respectively, and the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses cost 27,500 rupees, the company said. 'If we look at how the highest doses of Mounjaro and Wegovy are priced, it appears (that) Mounjaro's pricing is attractive and competitive,' said Vishal Manchanda from Systematix Institutional Equities. Wegovy's smallest doses of 0.25 mg, 0.5 mg and 1 mg cost 17,345 rupees a month, and its highest doses of 1.7 mg and 2.4 mg cost 24,280 rupees and 26,015 rupees a month, respectively. Lilly began selling Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since then, with sales in July doubling month-on-month. The drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
The Print
3 days ago
- Health
- The Print
Lilly launches Mounjaro pen in India at Rs. 14,000 for starting dose, stepping up Novo rivalry – ThePrint
Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply. Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device. Hyderabad: Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk. The smallest two doses are priced at 14,000 and 17,500 rupees, respectively, and the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses cost 27,500 rupees, the company said. 'If we look at how the highest doses of Mounjaro and Wegovy are priced, it appears (that) Mounjaro's pricing is attractive and competitive,' said Vishal Manchanda from Systematix Institutional Equities. Wegovy's smallest doses of 0.25 mg, 0.5 mg and 1 mg cost 17,345 rupees a month, and its highest doses of 1.7 mg and 2.4 mg cost 24,280 rupees and 26,015 rupees a month, respectively. Lilly began selling Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since then, with sales in July doubling month-on-month. The drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer. ($1 = 87.6650 Indian rupees) (Reporting by Kashish Tandon in Bengaluru and Rishika Sadam in Hyderabad; Editing by Janane Venkatraman) This report is auto-generated from Reuters news service. ThePrint holds no responsibility for its content.
